Janssen Biotech Signs Option Agreement With Molecular Partners On Use Of DARPins In Immunological Diseases
This article was originally published in The Pink Sheet Daily
Executive Summary
Switzerland's Molecular Partners extends collaboration with Janssen on novel proteins, DARPins, in immune indications.